Drug intelligence / Profile preview

DWP220

Development stage: Preclinical
Lead developer: Daewoong Pharmaceutical
Modality: Small Molecules
Administration: Oral

Overview

DWP220 is a small molecule inhibitor of NADPH oxidase 1 (NOX1) and NADPH oxidase 4 (NOX4) currently under development by Daewoong Pharmaceutical and its US-based affiliate, Great Bear Pharmaceutical. The drug is designed to treat fibrotic and inflammatory conditions, specifically metabolic dysfunction-associated steatohepatitis (MASH) and idiopathic pulmonary fibrosis (IPF). By inhibiting NOX1 and NOX4, DWP220 aims to reduce the production of reactive oxygen species (ROS), which are key mediators of oxidative stress, inflammation, and the activation of myofibroblasts that lead to tissue scarring. As of 2024, the program is in the preclinical stage of development.

Targets

NOX4 (NADPH oxidase 4)NOX1 (NADPH oxidase 1)

Beyond the preview

Go deeper on DWP220.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on DWP220.

Explore the full profile